Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Avenue Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +1 vs. Q3 2023
- Shares held
- 324.8K
- +102.1K (+45.8%) vs. Q3 2023
- Total value
- $52.4K
- −$104.8K (−66.7%) vs. Q3 2023
- New holders
- 5
- 3 more added
- Sold out
- 4
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATXI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 7 | $385.3K |
| Q3 2024 | 8 | $491.8K |
| Q2 2024 | 9 | $407.2K |
| Q1 2024 | 14 | $168.9K |
| Q4 2023 | 15 | $52.4K |
| Q3 2023 | 14 | $157.3K |
| Q2 2023 | 12 | $849.4K |
| Q1 2023 | 14 | $532.7K |
| Q4 2022 | 14 | $520.5K |
| Q3 2022 | 11 | $766.0K |
| Q2 2022 | 19 | $181.0K |
| Q1 2022 | 17 | $503.0K |
| Q4 2021 | 18 | $2.14M |
| Q3 2021 | 21 | $1.62M |
| Q2 2021 | 29 | $2.88M |
| Q1 2021 | 34 | $11.1M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Avenue Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 88,645 | $14.4K | 0.00% | +88,645 | New |
| Geode Capital Management, LLC | 52,160 | $8.48K | 0.00% | −411−0.8% | Reduced |
| Vanguard Group Inc | 46,293 | $7.45K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 30,593 | $4.97K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 28,605 | $4.65K | 0.00% | +28,605 | New |
| Two Sigma Securities, LLC | 27,500 | $4.43K | 0.00% | +13,062+90.5% | Added |
| HRT Financial LP | 25,283 | $4.00K | 0.00% | +25,283 | New |
| Cubist Systematic Strategies, LLC | 10,909 | $1.76K | 0.00% | +10,909 | New |
| Tower Research Capital LLC (TRC) | 6,814 | $1.10K | 0.00% | −62−0.9% | Reduced |
| Wells Fargo & Company | 4,624 | $745 | 0.00% | +39+0.9% | Added |
| BlackRock Inc. | 1,257 | $202 | 0.00% | −611−32.7% | Reduced |
| UBS Group AG | 1,080 | $174 | 0.00% | +1,080 | New |
| Emfo, LLC | 533 | $86 | 0.00% | 00.0% | Unchanged |
| Barrett & Company, Inc. | 15 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 514 | $0 | 0.00% | +416+424.5% | Added |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −51,572−100.0% | Sold out |
| Shikiar Asset Management Inc | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −276−100.0% | Sold out |